EN
Paysign's Patient Affordability Momentum Will Be Put to the Test
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Paysign typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-05 | +$0.31 (+3.34%) | $0.57 (6.20%) | +$2.81 (+29.30%) | $2.54 (26.49%) |
| 2026-05-12 | -$0.05 (-0.75%) | $0.64 (9.63%) | -$0.82 (-12.33%) | $1.30 (19.55%) |
| 2026-03-24 | +$0.43 (+12.87%) | $0.57 (17.07%) | +$1.38 (+36.60%) | $0.98 (25.86%) |
| 2025-11-12 | +$0.31 (+6.01%) | $0.41 (7.85%) | +$0.00 (+0.00%) | $0.92 (16.91%) |
| 2025-08-05 | -$0.04 (-0.56%) | $0.72 (10.05%) | -$1.90 (-26.69%) | $1.01 (14.19%) |
| 2025-05-08 | +$0.38 (+16.31%) | $0.45 (19.43%) | +$0.04 (+1.48%) | $0.22 (8.18%) |
| 2025-03-25 | -$0.04 (-1.59%) | $0.21 (8.25%) | -$0.21 (-8.47%) | $0.39 (15.73%) |
| 2024-11-05 | +$0.17 (+4.64%) | $0.21 (5.83%) | +$0.23 (+6.01%) | $0.26 (6.79%) |
| Avg Abs Move | 5.76% | 10.54% | 15.11% | 16.71% |
Paysign's post-earnings price action has been volatile and directionally mixed, with an average absolute Day 0 move of 5.76% and an average absolute Day +1 move of 15.11%. The Day +1 figure is particularly notable, suggesting the market often takes a full session to digest the results and adjust positioning.
The most dramatic recent move came after the August 5, 2026 report (Q2 2026), when the stock jumped 29.30% on Day +1 following a modest 3.34% gain on Day 0. That outsized reaction reflected the combination of a strong revenue beat, raised full-year guidance, and evidence that the patient affordability business was scaling faster than expected. The March 24, 2026 report (Q1 2026) also triggered a sharp rally, with the stock up 36.60% on Day +1 after a 12.87% Day 0 gain.
Conversely, the May 12, 2026 report saw the stock decline 12.33% on Day +1 despite a relatively flat Day 0 move, likely reflecting disappointment with the magnitude of the EPS miss or concerns about guidance. The August 5, 2025 report also triggered a sharp selloff, with the stock down 26.69% on Day +1.
The wide Day +1 range of 16.71% on average underscores the stock's sensitivity to earnings results and guidance, with investors reacting strongly to both upside and downside surprises. Based on historical patterns, investors should be prepared for a double-digit percentage move in either direction following the Q3 release, with the Day +1 session likely to be more volatile than the initial after-hours reaction.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 14) |
| Expected Move | $2.34 (15.92%) |
| Expected Range | $12.34 to $17.02 |
| Implied Volatility | 128.75% |
The options market is pricing a 15.92% expected move for Paysign around the November 20 expiration, which is roughly in line with the stock's average historical Day +1 move of 15.11% but slightly below the average Day +1 range of 16.71%. This suggests the options market is appropriately calibrated to the stock's recent earnings volatility, though it may be underpricing the potential for an outsized move similar to the 29.30% Day +1 surge seen after the Q2 2026 report.
Part 3: What Analysts Are Saying
Paysign enjoys strong analyst support, with a consensus rating that translates to 4.67 out of 5.0—firmly in buy territory. The breakdown shows 5 Strong Buy ratings, 0 Moderate Buy ratings, 1 Hold rating, and 0 Sell or Strong Sell ratings among the 6 analysts covering the stock.
The average price target of $14.10 implies modest upside of approximately -4.0% from the current price of $14.69, with a high target of $15.00 and a low target of $11.50. The relatively tight range suggests analysts are largely aligned on the company's near-term valuation, though the current price trading above the mean target indicates the stock has run ahead of consensus expectations following recent strength.
Analyst sentiment is classified as unchanged over the past month, with the Strong Buy/Hold breakdown holding steady at 5/1. However, the sentiment trend masks significant upward revisions to price targets earlier in 2026. Multiple firms lifted targets to $15 following the Q2 earnings beat and raised guidance, with commentary citing the company's ability to scale patient affordability programs, maintain strong win rates on RFPs, and expand margins. Analysts have highlighted the company's transformation from a prepaid card processor to a higher-margin healthcare payments platform as a key driver of the bullish thesis.
The consensus view reflects confidence in Paysign's dual-engine growth model—patient affordability programs driving revenue acceleration and plasma donor compensation providing a stable base—though the unchanged sentiment suggests analysts are waiting for Q3 results to determine whether further upward revisions are warranted or if the stock's recent run has fully priced in near-term upside.
Part 4: Technical Picture
Paysign's technical setup heading into earnings shows a stock that has built significant momentum over the past year but is currently consolidating near recent highs. The Barchart Technical Opinion stands at 88% Buy, up from 80% Buy a week ago and down slightly from 100% Buy a month ago, indicating strong but moderating bullish sentiment.
Timeframe Analysis:
- Short-term (50% Buy): The moderate buy signal suggests near-term momentum has cooled somewhat, likely reflecting the stock's consolidation after a strong run through mid-2026
- Medium-term (100% Buy): The maximum bullish reading indicates strong intermediate-term trend strength, consistent with the stock's sustained uptrend over the past several quarters
- Long-term (100% Buy): The maximum bullish reading reflects the stock's dramatic transformation over the past year, with the 200-day moving average serving as a key support level
Trend Characteristics: The signal is characterized as Strong in strength but Weakening in direction, suggesting the stock remains in a solid uptrend but may be losing some upward momentum heading into the earnings release.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $14.77 | 50-Day MA | $13.88 |
| 10-Day MA | $14.49 | 100-Day MA | $11.96 |
| 20-Day MA | $14.87 | 200-Day MA | $8.59 |
The stock is currently trading at $14.69, positioned below the 5-day moving average of $14.77 and below the 20-day moving average of $14.87, but above the 10-day ($14.49), 50-day ($13.88), 100-day ($11.96), and 200-day ($8.59) moving averages. This configuration suggests the stock is in a short-term consolidation phase within a longer-term uptrend.
The 71% gain from the 200-day moving average underscores the magnitude of the rally since early 2026, when the patient affordability business began to inflect. The stock's position just below the 5-day and 20-day averages suggests it has pulled back modestly from recent highs, potentially setting up a cleaner technical entry point for traders looking to position ahead of earnings. However, the weakening directional signal and the stock's proximity to resistance at the 20-day average suggest caution is warranted—a disappointing report could trigger a test of the 50-day moving average at $13.88, while a strong beat and raised guidance could propel the stock back toward the $15 level where it has encountered resistance in recent months.